Skip to content

The Ketamine Effect in Acute Asthma

The Effect of Low-Dose Ketamine in Treating Acute Asthma Attack

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015102912072N9
Enrollment
92
Registered
2015-11-14
Start date
2014-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Status asthmaticus

Interventions

Intervention 1: The intervention group will receive IV infusion Ketamine in 30 minutes (made by ROTEXMEDICA Company, Germany) with 0.3, 0.4, or 0.5 mg/kg doses in addition to the standard treatment. I
Treatment - Drugs
The intervention group will receive IV infusion Ketamine in 30 minutes (made by ROTEXMEDICA Company, Germany) with 0.3, 0.4, or 0.5 mg/kg doses in addition to the standard treatment
The control group will receive IV infusion Placebo in 30 minutes with the standard treatment

Sponsors

Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: patient's with mild to moderate asthma; patient's without any prohibition for using ketamine and history of allergic reaction. Exclusion Criteria: patient’s clinical condition worsened during the study; patient's needed mechanical ventilation; patient's who show ketamine side effects.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Peak Expiratory Flow Rate. Timepoint: at the study begining and every 30 minutes till 1 houre. Method of measurement: peak Flow Meter.

Secondary

MeasureTime frame
Clinical signs. Timepoint: at the study begining and every 30 minutes till 1 houre. Method of measurement: Clinical Examination.;Ketamine Complications. Timepoint: at the study begining and every 30 minutes till 1 houre. Method of measurement: Clinical Examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Esmailian

Isfahan University of Medical Sciences

m_esmailian@med.mui.ac.ir+98 31 3669 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026